Vivos Therapeutics, Inc. (NASDAQ: VVOS)

Vivos Therapeutics, Inc. specializes in developing and commercializing non-invasive, non-surgical oral appliance technologies designed to treat obstructive sleep apnea (OSA), snoring, and related dentofacial abnormalities. The company operates within the medical device sector, focusing on innovative solutions that address sleep-disordered breathing and associated conditions. Vivos Therapeutics leverages proprietary technologies to offer a range of FDA-cleared devices that cater to both adult and pediatric patients, providing alternatives to traditional treatments like continuous positive airway pressure (CPAP) machines and surgical interventions.

The company generates revenue through the sale of its FDA-cleared oral appliances, which include the DNA appliance, mRNA appliance, mmRNA appliance, Vivos Guides, Vivos Vida, Vivos Vida Sleep, and Vivos Versa. These devices are designed to treat mild to severe OSA, snoring, and other related conditions. Vivos Therapeutics serves a diverse customer base, including healthcare providers, dentists, and medical professionals who integrate these appliances into their treatment protocols. The company also collaborates with third-party suppliers and manufacturers to ensure the production and distribution of its products.

• Oral Appliance Segment: This segment encompasses the company's primary product offerings, including the DNA appliance, mRNA appliance, mmRNA appliance, Vivos Guides, Vivos Vida, Vivos Vida Sleep, and Vivos Versa. These devices are designed to treat obstructive sleep apnea, snoring, and related conditions. The DNA appliance is notable for being the only oral appliance cleared by the FDA to treat OSA in children. The Vivos Guides are used for orthodontic tooth positioning and have shown efficacy in addressing sleep-disordered breathing in pediatric patients. The mmRNA and mRNA appliances are cleared for treating mild to moderate OSA in adults, with additional clearance for moderate and severe OSA when used in conjunction with positive airway pressure (PAP) and/or myofunctional therapy. The Vivos Vida and Vivos Vida Sleep appliances are designed to treat symptoms such as TMJ/TMD, headaches, and facial muscle pain. The Vivos Versa is cleared for treating mild to moderate OSA in adults. These products cater to a broad market, including adults and children with sleep-disordered breathing and related conditions.

Vivos Therapeutics holds a unique position in the medical device industry, particularly in the treatment of sleep apnea and related conditions. The company's competitive advantages include its proprietary technologies, FDA clearances for its devices, and a strong focus on research and development. The FDA has granted the DNA appliance unprecedented clearance to treat children ages 6-17 for moderate to severe OSA, positioning Vivos Therapeutics as a leader in pediatric sleep apnea treatment. The company's devices are designed to be non-invasive and non-surgical, offering patients alternatives to more invasive treatments. Additionally, Vivos Therapeutics has established a robust intellectual property portfolio, including patents and trademarks, which helps protect its innovative technologies and competitive position.

The company's customer base includes healthcare providers, dentists, and medical professionals who utilize its oral appliances to treat patients with sleep-disordered breathing and related conditions. Vivos Therapeutics also collaborates with third-party suppliers and manufacturers to ensure the production and distribution of its products. The company's focus on ongoing clinical research and development further strengthens its position in the market, as it continues to invest in studies to improve its products and expand their applications.